Patrick Campbell

Tirzepatide, a dual GLP-1/GIP agonist approved for diabetes and obesity, was associated with significant blood pressure reductions in an analysis of the SURMOUNT-1 trial.

The FDA approval of Edwards Lifesciences EVOQUE tricuspid valve replacement system for treatment of symptomatic severe tricuspid regurgitation is the first of its kind for a transcatheter therapy.

Study presented at ISC 2024 suggests Black women with hypertension before age 35 face a 3-fold increase in risk of stroke while hypertension before 45 linked to doubling in stroke risk.

In the wake of Vera Therapeutics announcing positive 72-week data from the phase 2b ORIGIN trial, we sat down with lead investigator Richard Lafayette, MD, to learn more about how he interprets the latest data from the atacicept program in IgA nephropathy.

This endocrinology month in review spotlights FDA news, a pair of studies examining cardiovascular and renal risk reduction in type 2 diabetes, results from a subtrial examining testosterone’s effect on fracture risk, and 4 new episodes of diabetes dialgoue

In this feature, we acknowledge the impact of the 1964 Surgeon General report, its subsequent effect on public health, and present-day hurdles to optimized public health efforts through the eyes of our editorial advisory board members and other leading experts.

In an interview, Andrew Blauvelt, MD, MBA, provides further perspective on the approval of roflumilast topical foam, 0.3% (Zoryve) and full publication of phase 3 STRATUM data.

Study with 150,000 adults reveals 10% or more of unintentional weight loss associated with an elevated rate of cancer diagnosis within the next 12 months.

This cardiology case report from Brady Pregerson, MD, features a woman in her 50s presenting with 3 days of body swelling and dyspnea. Check out the EKG and see if you can determine the correct diagnosis!

A systematic review of over 400 studies in type 2 diabetes reveals 13 biomarkers, including NT-proBNP and troponin-t, with potential to significantly enhance cardiovascular disease risk prediction.

The 72-week open-label extension of the phase 2b ORIGIN trial reveals atacicept's potential as a disease-modifying treatment for IgA nephropathy, showing eGFR stabilization and improvements in key indicators

On January 25, 2024, the day following the proposed PDUFA goal date, Liquidia Corporation announced the FDA was still reviewing the NDA for pulmonary hypertension with interstitial lung disease for treprostinil inhalation powder (Yutrepia).

The American Heart Association's annual report on heart disease and stroke statistics for 2024 sheds new light on the impact and level of public education surrounding the impact of heart disease and stroke in the US and abroad.

A study of EHR workload trends reveals a concerning increase in primary care providers' time spent in the EHR post-pandemic, with providers spending 28 more minutes each workday on EHR-related tasks now relative to 2019.

Evidence from the Look AHEAD study suggests achieving remission in type 2 diabetes is associated with risk reductions in chronic kidney disease and cardiovascular disease.

In the CLEAR Outcomes trial, bempedoic acid was associated with a 20% reduction in relative risk for total cardiovascular events, with further analysis shining light on the effects of specific types of events.

Analysis finds measures of iron deficiency, including ferritin, serum iron, and transferrin, were linked to an increased likelihood of depression in young adult males but not females.

Results of the PRECISION trial suggest use of iron-whey-protein microspheres could aid in improving adherence to oral iron therapy as well as staving off adverse GI events.

A survey of more than 3000 US physicians is shedding light on the impact of taking vacation time and avoiding physician-related work on vacation can have on burnout and achieving professional fulfillment.

A study of more than 140 adults with diabetes is providing additional insight into the prevalence of anemia among these patients as well as its association with changes in glycemic control.

Applied Therapeutics announced topline results from ARISE-HF on January 04, 2023 and plans to present full results at an upcoming medical conference.

Our endocrinology month in review spotlights our most popular content from December 2023. Our list of the most popular content from the past month includes the ADA Standards of Care—2024, label updates, a feature from our This Year in Medicine series, and more!

Our cardiology month in review spotlights our most popular cardiology-centric content from the month of December 2023. The list includes topline data from SEQUOIA-HCM, new data on the impact of structural racism on chronic health conditions, and more!

Post hoc analysis of STRONG-HF trial underscores benefits of higher guideline-directed medical therapy doses in acute heart failure, showing lower rates of death or readmission at 6 months with more rapid uptitration.

On December 27, 2023, Cytokinetics announced positive topline results from the phase 3 SEQUOIA-HCM trial evaluating aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy

Study raises concerns about quality of care in the future, as results reveal private equity takeovers of hospitals associated with increased hospital-acquired adverse events, including falls and infections.

The FDA has approved eplontersen (Wainua) for treating polyneuropathy in adult patients with hereditary transthyretin-mediated amyloidosis, making it the only medication approved for self-administration via auto-injector pen for this condition.

A new study is raising awareness around the effects of structural racism on the prevalence of chronic health conditions.

Sex-based differences in hypertrophic cardiomyopathy outcomes reveal higher risks for women, including all-cause mortality.

Analysis of the NUDGE-FLU study reveals electronic nudges designed to boost influenza vaccination were more effective in older adults without diabetes, highlighting the need for tailored approaches in diabetes populations.